Recombinant, immunodominant antigens derived from Mycobacterium tuberculosis can be used to effectively vaccinate against subsequent infection. However, the efficacy of these recombinant proteins is dependent on the adjuvant used for their delivery. This problem affects many potential vaccines, not just those for tuberculosis, so the discovery of adjuvants that can promote the development of cell-mediated immunity is of great interest. We have previously shown that the combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and the immunomodulator modified lipid A synergistically potentiates Th1 T-cell responses. Here we report a screening program for other adjuvants with reported Th1-promoting activity and identify a second novel adjuvant formulation that drives the development of Th1 responses with an extremely high efficacy. The combination of dimethyl dioctadecyl ammonium bromide and the synthetic cord factor trehalose dibehenate promotes strong protective immune responses, without overt toxicity, against M. tuberculosis infection in a vaccination model and thus appears to be a very promising candidate for the development of human vaccines.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC356055 | PMC |
| http://dx.doi.org/10.1128/IAI.72.3.1608-1617.2004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Self-assembly of Dawson-type HPWO@[CuO(TZI)(HO)] for high-performance aerobic oxidation desulfurization of fuel.
Dalton Trans
July 2024
Key Laboratory of Functional Inorganic Material Chemistry (MOE), School of Chemistry and Materials Science, Heilongjiang University, Harbin 150080, Heilongjiang, China.
Because global sulfur emission has escalated, the development of high-efficiency deep desulfurization techniques has become imperative. Herein, to design a high-activity heterogeneous catalyst for the aerobic oxidation desulfurization (AODS) of fuel, Dawson-type polyoxometalate (HPWO abbreviated as D-PW), characterized by its high activity and strong oxidative capacity, was applied to react with CuCl·2HO and HTZI a one-pot hydrothermal method. Consequently, blue crystalline HPWO[CuO(TZI)(HO)] (abbreviated as D-PW@-MOF-1; -MOF-1 = [CuO(TZI)(HO)]·HO) was afforded.
View Article and Find Full Text PDFEnhanced efficacy of BCG vaccine formulated in adjuvant is dependent on IL-17A expression.
Tuberculosis (Edinb)
September 2024
Center for Biologics Evaluation and Research, United States Food and Drug Administration, Silver Spring, MD, USA.
A new, more effective vaccine against tuberculosis (TB) is urgently needed to curtail the current TB problem. The only licensed vaccine, BCG, has been shown to have highly variable protective efficacy in several clinical trials ranging from zero to 80 % against TB disease. We have previously reported that BCG formulated in dimethyl dioctadecyl-ammonium bromide (DDA) with D-(+)-Trehalose 6,6'-Dibehenate (TDB) adjuvant (BCG + Adj) is significantly more protective than BCG alone following murine aerosol Mycobacterium tuberculosis infection.
View Article and Find Full Text PDFProcess Optimization of Scaled-Up Production and Biosafety Evaluation of the Dimethyl-Dioctadecyl-Ammonium Bromide/Poly(lactic acid) Nano-Vaccine.
J Funct Biomater
May 2024
Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
Nano-adjuvant vaccines could induce immune responses and enhance immunogenicity. However, the application and manufacturing of nano-adjuvant is hampered by its challenging scale-up, poor reproducibility, and low security. Therefore, the present study aimed to optimize the preparation nanoparticles (NPs) using FDA-approved biopolymer materials poly(lactic acid) (PLA) and cationic lipid didodecyl-dimethyl-ammonium bromide (DDAB), develop the scale-up process, and evaluate the stability and biosafety of it.
View Article and Find Full Text PDFDimethyl-Dioctadecyl-Ammonium Bromide/Poly(lactic acid) Nanoadjuvant Enhances the Immunity and Cross-Protection of an NM2e-Based Universal Influenza Vaccine.
ACS Nano
May 2024
Key Laboratory of Green Process and Engineering, State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, P.R. China.
Article Synopsis
- There is a pressing need for a universal influenza vaccine that can protect against different virus types, and a new fusion protein vaccine called NM2e has been developed, but improvements are required for better immune responses.
- Researchers created a new nanovaccine called NM2e@DDAB/PLA by combining NM2e with a special nanoadjuvant, which showed improved activation of immune cells in laboratory tests.
- In live animal studies, the new nanovaccine effectively stimulated immunity, stayed in the body’s lymph nodes for an extended period, and offered over 90% protection against various influenza strains, indicating its potential as a universal vaccine solution.
Starch/poly (butylene adipate-co-terephthalate) blown films contained the quaternary ammonium salts with different N-alkyl chain lengths as antimicrobials.
Food Chem
March 2024
College of Food Science and Engineering, Shandong Agricultural University, Tai'an, Shandong Province, 271018, China. Electronic address:
Antimicrobial biodegradable packaging is in high demand as a one-two punch against microbiological and plastic hazards. Two quaternary ammonium salts (QAS) with different N-alkyl chain lengths were used for starch/poly (butylene adipate-co-terephthalate) (PBAT) blown antimicrobial films. Dioctadecyl dimethyl ammonium chloride (D1821) contributed to a homogeneous film morphology at 5% w/w level, while micro-pores occurred with didodecyl dimethyl ammonium chloride (D1221).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!